Limited clinical studies exist on the combined use of neoadjuvant CT (NACT) and neoadjuvant ET (NET), and there are no reported instances of concurrent neoadjuvant treatment for locally advanced breast cancer (LABC) using capecitabine and fulvestrant (FUL).<h4>Case presentation</h4>We reported a 54-year-old woman who was diagnosed with hormone receptor-positive (HR+) LABC at our hospital. This evidence concerns the gene NR4A1 and breast carcinoma.